M0249 Tocilizumab IV Infusion Reimbursement | OpenPayer

Summary & Overview

HCPCS M0249: Tocilizumab IV Infusion for Hospitalized COVID-19 Patients, First Dose

HCPCS Level II code M0249 identifies the first-dose intravenous infusion of tocilizumab for hospitalized adults and pediatric patients (aged 2 years and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). This code captures both the infusion procedure and immediate post-administration monitoring, reflecting care delivered in acute inpatient settings and intensive care units. Nationally, use of a specific HCPCS Level II code for tocilizumab in this clinical context supports accurate billing, utilization tracking, and policy alignment for COVID-19 therapeutics administered in hospitals.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for M0249, payer coverage relevance, and what to expect from the code’s use in hospital-based COVID-19 treatment. The publication outlines benchmarks where available, recent policy and coding updates applicable to hospital-administered COVID-19 monoclonal antibody therapy, and practical considerations for service line classification and site-of-service reporting. Data not available in the input will be identified as such.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM0249HCPCS Level IItocilizumabCOVID-19intravenous infusionhospital inpatientcritical caremonoclonal antibodyfirst dose

Billing Code Overview

HCPCS Level II code M0249 represents the intravenous infusion of tocilizumab for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The code includes the infusion and post-administration monitoring for the first dose.

Service Type: Intravenous therapeutic infusion (first dose) of a monoclonal antibody (tocilizumab) for hospitalized COVID-19 patients requiring advanced respiratory support while on systemic corticosteroids.

Typical Site of Service: Hospital inpatient setting, including intensive care units and acute care wards where patients receive supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO support.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A hospitalized adult or pediatric patient (age ≥2 years) with confirmed COVID-19 develops progressive hypoxemic respiratory failure despite systemic corticosteroid therapy and requires supplemental oxygen, high-flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation. The treating team orders M0249 for intravenous tocilizumab (first dose) to address severe inflammatory response. The clinical workflow includes verification of indication and weight-based dosing, pharmacy preparation of the infusion, placement of an appropriate IV or central line, administration of the infusion over the recommended time, and monitored recovery during the post-administration observation period. Documentation includes indication, consent, dose and lot numbers, infusion start and stop times, patient vital signs and oxygen requirements before, during, and after infusion, and any adverse reactions and management. Typical sites of service are the inpatient acute care hospital, intensive care unit, or pediatric inpatient unit. Common payors involved in billing and prior authorization processes include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Use when no specific modifier applies and insurer requires an explicit primary modifier field.

HCPCS Level II M0234: Tocilizumab-aazg IV Infusion, Second Dose

HCPCS-M0076-PROLOTHERAPY-INJECTION-THERAPY

HCPCS M0076: Prolotherapy Injection Therapy

HCPCS-M0223-BEBTELOVIMAB-INTRAVENOUS-INJECTION-HOME-MONITORING

HCPCS M0223: Bebtelovimab IV Injection with Home Monitoring

HCPCS-M0235-MONOCLONAL-ANTIBODY-INFUSION-HOSPITALIZED-COVID19

HCPCS M0235: Monoclonal Antibody Infusion for Hospitalized COVID-19 Patients

HCPCS-M0300-IV-CHELATION-CHEMICAL-ENDARTERECTOMY

HCPCS M0300: IV Chelation Therapy (Chemical Endarterectomy)

HCPCS-M0240-CASIRIVIMAB-IMDEVIMAB-INFUSION-INJECTION-MONITORING

HCPCS M0240: Casirivimab and Imdevimab Infusion or Injection with Monitoring

HCPCS-M0100-INTRAGASTRIC-HYPOTHERMIA-GASTRIC-FREEZING

HCPCS M0100: Intragastric Hypothermia Using Gastric Freezing

HCPCS-M0239-INTRAVENOUS-BAMLANIVIMAB-INFUSION-WITH-MONITORING

HCPCS M0239: Intravenous Infusion of Bamlanivimab with Monitoring

HCPCS-M0301-FABRIC-WRAPPING-ABDOMINAL-ANEURYSM

HCPCS M0301: Fabric Wrapping of Abdominal Aneurysm

HCPCS-M0247-SOTROVIMAB-INTRAVENOUS-INFUSION-WITH-MONITORING

HCPCS M0247: Intravenous Infusion of Sotrovimab, Includes Monitoring

Showing 1–10 of 27

Taxonomy Code	Specialty	Notes
`207P00000X`	Critical Care Medicine	Intensivists commonly order and oversee administration for severely ill patients.
`207R00000X`	Pulmonary Disease	Pulmonologists manage respiratory failure and indications for immunomodulatory therapy.
`207RC0000X`	Pediatric Critical Care Medicine	Pediatric intensivists manage children meeting criteria for `M0249`.
`363LP0808X`	Hospitalist	Hospitalists coordinate inpatient care, orders, and documentation for infusion.
`2084P0800X`	Infectious Disease	Infectious disease specialists advise on indications and infectious considerations for tocilizumab.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J12.82`	Pneumonia due to coronavirus disease 2019	Common primary diagnosis for hospitalized COVID-19 patients receiving tocilizumab.
`J96.01`	Acute respiratory failure with hypoxia	Indicates respiratory failure requiring supplemental oxygen or ventilatory support, consistent with `M0249` criteria.
`J80`	Acute respiratory distress syndrome	Severe pulmonary inflammation that may prompt immunomodulatory therapy.
`M35.81`	Multisystem inflammatory syndrome	In pediatric patients with severe inflammatory response related to COVID-19, may support use of immunomodulators.
`R65.2`	Severe sepsis with septic shock	If superimposed or overlapping cytokine storm physiology, may be relevant to treatment decisions.
`Z79.52`	Long term (current) use of systemic steroids	Documentation of concurrent systemic corticosteroid therapy required by the `M0249` description.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	May be used for billing facility infusion services when payer requires CPT for infusion time-based billing alongside `M0249` when reporting per-payer rules.
`96366`	Intravenous infusion, each additional hour (list separately in addition to code for primary infusion)	Use when infusion duration extends beyond the initial hour and CPT-based time reporting is required by the payer.
`36415`	Collection of venous blood by venipuncture	Performed before or after infusion for laboratory monitoring (e.g., inflammatory markers, drug safety labs).
`36556`	Placement of non-tunneled centrally inserted central venous catheter; age 5 years or older	Used if central venous access is required to administer the infusion in critically ill patients.
`99024`	Postoperative follow-up visit global period, related to procedure; rarely used	Applicable only per payer policy when reporting additional post-procedure evaluation beyond included monitoring; many payers consider post-infusion monitoring included in `M0249`.

OpenPayer